NEW
YORK, July 24, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today announced that the Company will participate in the 2nd Annual
Targeted Radiopharmaceuticals Summit in Boston, July 25 - 27,
2023. Actinium will present "Targeted Radiotherapeutics
& Innovative Combinations to Alter the Treatment Outcome for
Conditioning, Hematological & Solid Tumor Malignancies" on
Thursday, July 27, 2023 at
12:30pm ET.
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other blood
cancers and next generation conditioning candidate Iomab-ACT to
improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma for
solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid
tumors, and EpicentRx for its CD47 targeting agent, and several
internal programs in solid tumors. Actinium holds more than 200
patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-to-present-at-the-2nd-annual-targeted-radiopharmaceuticals-summit-301883264.html
SOURCE Actinium Pharmaceuticals, Inc.